Navigation Links
BioMarin to Present at the Barclays Global Healthcare Conference
Date:3/8/2011

NOVATO, Calif., March 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Barclays Global Healthcare Conference in Miami on Tuesday, March 15, 2011 at 4:15 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical d
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin to Present at the Cowen Health Care Conference
2. BioMarin to Present at the Citi Global Healthcare Conference
3. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
4. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
5. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
6. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
7. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
8. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
9. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
10. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
11. BioMarin Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014  Training market researchers to spot and ... in today,s highly competitive global marketplace. As resources ... effectively and efficiently produce high performing analysts, regardless ... Effective training programs can help these ... internal clients by developing analysts who can drive ...
(Date:10/17/2014)... -- Research and Markets  has announced the ... of China Dialysis Market, 2014-2018" report to ... 2013 version, this update Report provides detailed analysis ... the relevant effect in recent three years, and ... it analyzes Chinese private-owned hemodialysis services. In the ...
(Date:10/17/2014)... BALTIMORE, Md. , Oct. 17, 2014 /PRNewswire-USNewswire/ ... Center for Medical Technology Policy: The ... from the FDA, public and private payers, medical ... representatives, clinicians, and other experts January 12, 2015 ... effectiveness and value of weight loss treatments.  Participants ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
(Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
(Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... spondylitis is a systemic disease that causes inflammation ... have affected members of the ancient Egyptian royal ... Arthritis & Rheumatology , a journal of the ... finding instead a degenerative spinal condition called diffuse ... from the 18th to early 20th Dynasties. ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... , , TULSA, Okla., ... its service area across Oklahoma by partnering with several EMS providers ... 1st, 2009. , , Since the commercial ... 1.3 million people served by the Emergency Medical Services Authority (EMSA) ...
... finds more evidence in areas where more men ... -- High levels of persistent environmental chemicals are ... countries with high rates of male reproductive problems, ... endocrine-disrupting chemicals, or EDCs, are commonly found in ...
... , , EMERYVILLE, Calif., Sept. ... today announced that it will webcast an investor briefing on ... Speakers will review clinical data for Nexavar in breast cancer ... European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin. ...
... , LAKE FOREST, Ill., Sept. 24 ... pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of ... Paladin Labs, Inc. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ... to Bioniche,s product offering further broadens our base of niche ...
... introduction of statins to treat high cholesterol, the decline ... double that experienced by the poor. While statins ... health, their use may have contributed to expanding social ... research by Virginia W. Chang, MD, PhD, of the ...
... , , NEW ... market research report is available in its catalogue. , ... Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays ... http://www.reportlinker.com/p0119228/H1N1-(Swine-Influenza)-Market-Assessment-(Latest-Data-Company-Profiles-Implications-for-Immunoassays-and-Molecular-Assays).html , , ...
Cached Medicine News:Health News:Oklahoma Medics Embracing iB Web Service 2Health News:Environmental Chemicals May Affect Male Reproduction 2Health News:Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 3Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 4
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
... is designed for third degree ... as a cystocele and rectocele. ... both with and without drainage ... tie to aid in removal. ...
... Gellhorn Pessary is used for ... prolapse, or procidentia. It has ... and comes in nine sizes. ... easily folds over for insertion, ...
Medicine Products: